HRT Financial’s Aurinia Pharmaceuticals AUPH Stock Holding History

HRT Financial’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-211,025	Closed	-$3.13M	–	4160
2026 Q1	$3.13M	Buy	211,025 +128,791	+157%	+$1.88M	0.01%	1290
2025 Q4	$1.31M	Buy	82,234 +41,394	+101%	+$587K	﹤0.01%	1560
2025 Q3	$451K	Buy	+40,840	New	+$446K	﹤0.01%	1948
2024 Q1	–	Sell	-30,761	Closed	-$276K	–	2300
2023 Q4	$276K	Sell	30,761 -3,775	-11%	-$31.1K	﹤0.01%	1655
2023 Q3	$268K	Sell	34,536 -70,687	-67%	-$691K	﹤0.01%	1713
2023 Q2	$1.02M	Buy	105,223 +15,158	+17%	+$157K	0.01%	941
2023 Q1	$987K	Buy	+90,065	New	+$793K	0.01%	955
2022 Q2	–	Sell	-38,755	Closed	-$479K	–	2910
2022 Q1	$479K	Buy	+38,755	New	+$599K	﹤0.01%	1873
2021 Q3	–	Sell	-96,892	Closed	-$1.25M	–	3263
2021 Q2	$1.25M	Buy	+96,892	New	+$1.23M	0.01%	881

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRT Financial's AUPH Position: Q2 2026 in Review

HRT Financial sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2026, closing a stake of 211,025 shares — an estimated $3.13M sold.

HRT Financial first reported a position in AUPH in Q2 2021 and held it in 9 quarters. The position peaked at $3.13M in Q1 2026. 282 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

HRT Financial reported no remaining Aurinia Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
HRT Financial sold 211,025 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $3.13M.
HRT Financial first reported a position in Aurinia Pharmaceuticals in Q2 2021 and held it in 9 quarters.
HRT Financial's Aurinia Pharmaceuticals position peaked at $3.13M in Q1 2026.
282 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.